285 related articles for article (PubMed ID: 26918448)
41. Identification of epidermal growth factor receptor and its inhibitory microRNA141 as novel targets of Krüppel-like factor 8 in breast cancer.
Li T; Lu H; Mukherjee D; Lahiri SK; Shen C; Yu L; Zhao J
Oncotarget; 2015 Aug; 6(25):21428-42. PubMed ID: 26025929
[TBL] [Abstract][Full Text] [Related]
42. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
43. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.
Patel JB; Appaiah HN; Burnett RM; Bhat-Nakshatri P; Wang G; Mehta R; Badve S; Thomson MJ; Hammond S; Steeg P; Liu Y; Nakshatri H
Oncogene; 2011 Mar; 30(11):1290-301. PubMed ID: 21057539
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
45. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer.
Jin L; Wessely O; Marcusson EG; Ivan C; Calin GA; Alahari SK
Cancer Res; 2013 May; 73(9):2884-96. PubMed ID: 23338610
[TBL] [Abstract][Full Text] [Related]
46. ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation.
Yuan Y; Anbalagan D; Lee LH; Samy RP; Shanmugam MK; Kumar AP; Sethi G; Lobie PE; Lim LH
Oncotarget; 2016 May; 7(19):27007-20. PubMed ID: 27105503
[TBL] [Abstract][Full Text] [Related]
47. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
Zhou X; Agazie YM
J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
[TBL] [Abstract][Full Text] [Related]
48. miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer.
Guo J; Gong G; Zhang B
Sci Rep; 2018 Feb; 8(1):2073. PubMed ID: 29391441
[TBL] [Abstract][Full Text] [Related]
49. HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer.
Zhou Y; Yuan Y; Li L; Wang X; Quan Y; Liu C; Yu M; Hu X; Meng X; Zhou Z; Zhang CY; Chen X; Liu M; Wang C
PLoS One; 2021; 16(2):e0245832. PubMed ID: 33529238
[TBL] [Abstract][Full Text] [Related]
50. miR-506 regulates breast cancer cell metastasis by targeting IQGAP1.
Sun G; Liu Y; Wang K; Xu Z
Int J Oncol; 2015 Nov; 47(5):1963-70. PubMed ID: 26398880
[TBL] [Abstract][Full Text] [Related]
51. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
52. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8.
Li M; Tian L; Ren H; Chen X; Wang Y; Ge J; Wu S; Sun Y; Liu M; Xiao H
J Transl Med; 2015 Aug; 13():271. PubMed ID: 26286725
[TBL] [Abstract][Full Text] [Related]
54. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
55. The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers.
Maqbool R; Rashid R; Ismail R; Niaz S; Chowdri NA; Hussain MU
Cell Oncol (Dordr); 2015 Dec; 38(6):443-51. PubMed ID: 26335100
[TBL] [Abstract][Full Text] [Related]
56. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Zhao H; Martin E; Matalkah F; Shah N; Ivanov A; Ruppert JM; Lockman PR; Agazie YM
Oncogene; 2019 Mar; 38(13):2275-2290. PubMed ID: 30467378
[TBL] [Abstract][Full Text] [Related]
57. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
[TBL] [Abstract][Full Text] [Related]
58. Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
Maleki E; Ghaedi K; Shahanipoor K; Karimi Kurdistani Z
APMIS; 2018 Apr; 126(4):303-308. PubMed ID: 29575198
[TBL] [Abstract][Full Text] [Related]
59. Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks Tumorigenesis.
Kumar AS; Jagadeeshan S; Pitani RS; Ramshankar V; Venkitasamy K; Venkatraman G; Rayala SK
Mol Cell Biol; 2017 Mar; 37(6):. PubMed ID: 27956702
[TBL] [Abstract][Full Text] [Related]
60. miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.
Lindholm EM; Leivonen SK; Undlien E; Nebdal D; Git A; Caldas C; Børresen-Dale AL; Kleivi K
Microrna; 2019; 8(2):155-165. PubMed ID: 30520388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
